Danish Pharmacovigilance Update 28 November 2013

03 February 2014

In this issue of Danish Pharmacovigilance Update:

News from the EU

  • Acipimox (Olbetam®) should only be used to lower triglycerides when other treatments of dyslipidaemia are not sufficient
  • Risk of blood clots from the use of the cancer medicine ponatinib (Iclusig®)
  • All patients should be screened for hepatitis B virus (HBV) before starting treatment with rituximab (Mabthera®)
  • Preparation error resulting in overdose of cabazitaxel (Jevtana)

News from the Danish Health and Medicines Authority

  • Ciprofloxacin and the risk of tendon disorders
  • Decrease in the use of medicines for the treatment of anogenital warts in adolescents under the age of 20
  • Bisphosphonates/denosumab and the risk of osteonecrosis of the jaw
  • The tugboats of preventive health – an article from the Danish weekly newspaper Weekendavisen

Short news

  • Batches of the NovoMix®30 FlexPen® recalled
  • Reporting of adverse reactions to the Danish Health and Medicines Authority
  • Danish Pharmacovigilance Update celebrates its 4th anniversary